A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 43
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : sPD-L1
Long Form : soluble programmed death ligand 1
No. Year Title Co-occurring Abbreviation
2020 Clinical implications of APOBEC3A and 3B expression in patients with breast cancer. A3A
2020 Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. HCC, TACE
2020 High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma. NPC
2020 Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: A monocentric cross-sectional study. ILD, RA
2020 Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. anti-PD-1, NSCLC, PFS, sCD40L, sCD44, sPD-1, VEGF-A
2020 Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment. EPI, HBV, HCs, sPD-1
2020 Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity. ELISA, PD-1, PD-L1, sPD-1, sPD-1
2020 Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. OS, PCNSL, PD-1, PD-L1, PFS
2020 The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas. CSF, ELISA, HCs
10  2019 A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma. RCC
11  2019 Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. miRNAs, NSCLC, PS
12  2019 Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer. DFS, PTC
13  2019 Long-term Host Immune Response Trajectories Among Hospitalized Patients With Sepsis. HR, hs-CRP
14  2019 Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study. ELISA, NPC
15  2019 Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas. ELISA, IHC, PTCL
16  2019 Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis. PTCL
17  2019 Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients. HCC, OS
18  2019 The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. DFS, HCC, HR, OS, PD-L1, sPD-1, TILs
19  2018 Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. HCC, RT, SBRT
20  2018 Evidence for Persistent Immune Suppression in Patients Who Develop Chronic Critical Illness After Sepsis. ALCs, CCI, mHLA-DR, RAP
21  2018 High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma. ELISA, HL, PFS
22  2018 Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. CRDM, DM, HC, IQR, ROC, TIF1-gamma
23  2018 Multiplexed SERS Detection of Soluble Cancer Protein Biomarkers with Gold-Silver Alloy Nanoboxes and Nanoyeast Single-Chain Variable Fragments. sEGFR, sPD-1
24  2018 Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis. HRs
25  2018 Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer. NSCLC, OS, PD-1, TTF
26  2018 Soluble programmed death-1 ligand 1(sPD-L1) is significantly reduced in the serum of type 1 diabetes patients. ---
27  2018 [Selection of Chemotherapy Regimen on the Basis of Monitoring NLR and Soluble PD-L1 during CRC Chemotherapy]. NLR
28  2017 Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C. CHB, CHC, IFN, SMV, SVR, TVR
29  2017 Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients. AR, ARIA, PD-L1
30  2017 Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. NSCLC, OS, TRT
31  2017 Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. PC, sPD-1
32  2017 The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis. HRs, OS
33  2017 [Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer]. RAU, sPD-1
34  2016 High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. HCC, OS, PD-L1
35  2016 High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. ENKTCL, OS, PFS
36  2016 [Increased serum levels of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients infected with Brucella]. CBA, sPD-1, sPD-1
37  2016 [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications]. CEA, DC group, EGFR, ELISA, ROC, TKI, TNAB, WT
38  2015 Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. MM, OS, PFS, PR
39  2015 [Effects of soluble programmed death ligand 1 on regulating the proliferation of T lymphocytes and its mechanism]. PD-1, PHA
40  2015 [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus]. OLP, sPD-1
41  2014 High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. DLBCL, OS
42  2014 [Level of soluble programmed death ligand 1 in pleural effusion and peripheral blood of patients with tuberculous pleural effusion and its clinical implications]. ADA, AUC, ELISA, MMP-3, MPE, PD-L1, ROC, RT-PCR, TPE
43  2012 [The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications]. ---